Most molecular tests hide their answer inside a machine. You load the sample, wait, and trust a fluorescence reader to tell you whether a virus is there. That works well in a hospital lab. It fails at a rural clinic, a border checkpoint, or a poultry shed, where the reader, the cold chain, and the trained hands are all in short supply. A group of chemists at Nantong University in China set out to strip the machine away and leave something a person can simply look at.
Their answer, reported in Analytical Chemistry, is a CRISPR-based test that goes green when it finds the genetic signature of a pathogen. No color at the start, a clear green if the target is present. The team validated it on the monkeypox virus in environmental samples and on respiratory syncytial virus, or RSV, in patient specimens, and it agreed with standard PCR on all 40 samples it was checked against.
Borrowing a trick from DNA origami
The clever part is how the color gets made. CRISPR diagnostics usually rely on a Cas enzyme that, once it recognizes its target, starts chopping up any nearby single-stranded DNA. Most designs use that chopping to release a fluorescent tag, which is why they need a reader. This test instead ties the enzyme's activity to a G-quadruplex, a knot-like fold of guanine-rich DNA that can act like an enzyme itself. When a G-quadruplex grabs a small molecule called hemin, the pair behaves like a peroxidase and drives a reaction that produces green color.
The researchers split the G-quadruplex into two useless halves and held them apart. Only when the Cas enzyme detects the virus and cuts the tethers do the halves come together, fold into the working shape, and switch on the color reaction. Because the signal turns on rather than off, a positive result is a fresh green against a colorless background, which is easier to read by eye than a dimming glow. The design works with both Cas12 and Cas13, the two enzymes that cover DNA and RNA targets, so the same chemistry can be pointed at a range of viruses.
One tube, no cross-contamination
A practical headache with these amplified tests is contamination. To get down to a single copy of viral material, you first copy the target many times using a method called recombinase polymerase amplification, which runs at body temperature without a thermal cycler. That amplification step generates billions of copies, and if the tube is opened to add the CRISPR reagents, stray copies can drift onto benches, pipettes, and the next sample, producing false positives that haunt a lab for weeks.
The Nantong team avoided opening the tube at all. They built what they call a tube-in-tube cartridge: the amplification happens in an inner compartment, and the CRISPR detection reagents wait in the outer one until a simple step releases them, all without breaking the seal. The whole run finishes in under an hour and reaches a detection limit of one copy per test, which is about as sensitive as molecular tests get.
What the study can't say yet
This is a proof-of-concept, and the sample numbers are small. Forty specimens with perfect agreement against PCR is encouraging, but it is not the hundreds or thousands of clinical samples, drawn from different sites and patient groups, that a diagnostic needs before anyone can trust it in the field. Perfect concordance on a modest panel can slip once the test meets messier real-world specimens with low viral loads or unusual variants.
There are other open questions. Reading a color by eye is subjective, and faint positives near the detection limit may be hard to call without a phone camera or a simple reader to standardize the judgment. The recombinase amplification chemistry, while it avoids a thermal cycler, still uses reagents that are sensitive to storage and can be fussy about primer design. And the test has been shown on monkeypox and RSV, not yet on the crowded, competing targets found in a real respiratory swab during flu season.
Still, the direction is worth watching. A closed, single-tube CRISPR test that any user can read as a color change, works for both DNA and RNA viruses, and needs no cold instrument is exactly the kind of tool that could push accurate diagnosis out of the central lab and toward the places where outbreaks actually start. Monkeypox and RSV are apt first targets: one keeps flaring in places without dense lab infrastructure, and the other fills pediatric wards every winter. If the approach holds up on larger cohorts, the machine that used to read the answer might become optional.
Comments